Todd C Davis bought $1.0M of Ligand Pharmaceuticals Incorporated (LGND)
Executed May 9 2025, disclosed May 13 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (May 13 2025), the stock returned +8.5% (delay-adjusted); from the execution session (May 9 2025), +7.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Todd C Davis (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Ligand Pharmaceuticals Incorporated (LGND). Across 1 priced purchase filing, the average 21-session return was -5.4% from execution and -2.9% from disclosure (delay-adjusted; derived). The largest single filing was $986K of PTHS (35,445 sh × $27.80, as filed), executed Jun 11.
Healthcare · Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→